Tweet
<img alt="" height="1" width="1" />
Amgen drug cuts prostate cancer bone problem risk
Reuters
CHICAGO (Reuters) - A third pivotal trial of Amgen Inc's denosumab found that it delayed by 21 percent the risk of fractures and other bone complications in men with advanced prostate cancer compared with current therapy. Amgen filed last month for US ...
Amgen Drug Shown to Delay Fractures in Cancer PatientsWall Street Journal
Amgen Drug Delays Cancer Patients Fractures Longer Than ZometaBusinessWeek
Amgen Osteoporosis Drug Helps Cancer Patients Fight FracturesSmartAboutHealth
PR Newswire (press release) -TopNews United Kingdom (blog)
all 36 news articles »
More...